Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages 571-577

  Salasche, Stuart J ^a   Levine, Norman ^a   Morrison, Lynne ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; DICLOFENAC; FLUOROURACIL; HYDROXYACID; IMIQUIMOD; RETINOID;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CHEEK; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EROSION; ERYTHEMA; EXUDATE; FACE; FEMALE; FEVER; FLU LIKE SYNDROME; FOREHEAD; HUMAN; IMMUNOTHERAPY; MALE; MUSCLE FATIGUE; MUSCLE WEAKNESS; OPEN STUDY; PAIN; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; REMISSION; SCALP; SCHOOL CHILD; SKIN EDEMA; SKIN INDURATION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN TOXICITY; SKIN ULCER; TREATMENT OUTCOME;

EID: 0036788815     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.126257     Document Type: Article

References (25)

1. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42(Suppl):S23-s24.
2. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000;42(Suppl):S11-S17.
3. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998;37:677-81.
4. Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South Med J 2000;93:846-50.
5. Goette DK. Topical chemotherapy with 5-fluorouracil. J Am Acad Dermatol 1981;4:633-9.
6. Pearlman L. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991;25:665-7.
7. Unis ME. Short term intensive 5-fluorouracil treatment of actinic keratoses. Dermatol Surg 1995;21:162-3.
8. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:S25-S28.
9. Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett 2001;6:1-4.
10. Rivers JK, McLean DI. An open label study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997;133:1239-42.
11. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001;45:96-104.
12. Kurwas HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratosis. J Am Acad Dermatol 1999;41:414-8.
13. Stockfleth E, Meyer T, Benninghoff B, Christopher E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of a 6 cases. Br J Dermatol 2001;144:1050-8.
14. Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002;47:553-6.
15. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, et al. A randomized, double blind, vehicle controlled study to assess imiquimod 5% for the treatment of multiple actinic keratoses. Arch Dermatol. In press.
16. Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001;137:709-11.
17. Mackenzie-Wood A, Kossard 5, deLauncey J, Wilkinson B, Owens M. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44:42-70.
18. Marks R, Gebauer K, Shumack S. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
19. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1991;41:1002-7.
20. Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smithe MH, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream, 5%. Antiviral Res 1999;43:55-63.
21. Imbertson LM, Beaurline JM, Couture AM, Gibson JS, Smith RMA, Miller RL, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers, imiquimod and S-28463. J Invest Dermatol 1998;110:734-9.
22. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RJ, Smith RM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191:10-9.
23. Feldman SR, Fleischer AB, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol 1999;40:43-7.
24. Hemmi HT, Kaisho O, Takeuchi S, Sato H, Hoshino T, Horiuchi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology 2002;3:196-200.
25. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998;38:77-80.